AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN ANTONIO -- Tamoxifen markedly reduces the incidence of most forms of benign breast disease, Dr. Elizabeth Tan-Chiu said at the annual breast cancer symposium sponsored by the San Antonio Cancer Institute.
She reported on 13,388 women at high risk for developing breast cancer who were randomized to tamoxifen or placebo in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (NSABP BCPT P-1). In 1998 this landmark trial demonstrated that tamoxifen reduced the incidence of invasive breast cancer by 49% and of noninvasive cancer--ductal carcinoma in situ and lobular carcinoma in situ--by 50%.
Now NSABP P-1 investigators have turned their attention to benign breast disease. At a median 54.6 months of follow-up, the overall risk of benign breast disease in the tamoxifen-treated group was reduced by 28%, compared with women on placebo, reported Dr. Tan-Chiu of the NSABP operations office in Pittsburgh.
Total breast biopsies were 22% fewer in the tamoxifen group than the 1,804 biopsies performed in controls. Moreover, the use of tamoxifen reduced by 12% the number of women who experienced at least one biopsy, from 1,242 to 1,098.
"The finding of a tamoxifen effect in benign breast tissue supports its ...